- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07783880
Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes (DCB-PE)
Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes
Drug eluting balloon angioplasty might be a better alternative than medical treatment or stenting in subjects with plaque erosion, which is the second most common cause of myocardial infarction.
The main objective of this pilot study is to gain clear insights on the effect of percutaneous coronary intervention (PCI) with size matched DCB (SeQuent) as compared to treatment with GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy in a predominantly Caucasian population at 2 days and at 1 year after the procedure.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Prof. Elvin Kedhi, MD PhD
- Telefonnummer: +1 514-934-1934
- E-post: ekedhi@me.com
Studiesteder
-
-
-
Lubin, Polen
- Miedziowe Centrum Zdrowia SA
-
Ta kontakt med:
- Dr. hab. n. med. Adrian Wlodarczak
- Telefonnummer: +48 76 846 03 00
- E-post: wlodarczakadrian@gmail.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Patients aged ≥18 years presenting with MI where the culprit de-novo (stent restenosis/thrombosis excluded) lesion has a Thrombolysis in Myocardial Infarction (TIMI) flow of ≥ I with signs of thrombus on angiographic (or CCTA followed by conventional coronary angiography) evaluation located in a native coronary artery (a by-pass graft vessel excluded) addressable by PCI;
OCT criteria (all 4 should be present):
- Presence of thrombus
- Absence of an overt ruptured plaque flap
- Area of stenosis of ≥ 50%
- Presence of atherosclerotic, predominantly lipidic or fibrotic plaque underneath (absence of major calcifications or calcified noduli)
Exclusion Criteria:
- Culprit lesion located or extending in the Left Main coronary artery;
- Presence of large coronary aneurysms;
- Large thrombus burden (extending for more than > 15 mm);
- Patients with severe tortuous lesions (OCT judged not possible);
- Spontaneous coronary dissection is suspected;
- Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5);
- Life expectancy less than 2 years;
- Pregnant or lactating women;
- Patients currently participating in another trial;
Patients that are unable or unwilling to provide consent;
OCT exclusion criteria:
- Overt plaque rupture;
- Thrombosed protruding calcified noduli;
- Predominantly calcific lesions with calcium arc > 180° in the target segment;
- Presence of calcium plaque of > 0.4 mm thick;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: PCI with size matched DCB
PCI with size matched drug-coated balloon
|
Subjects will be treated with PCI with size matched DCB (SeQuent)
|
|
Placebo komparator: GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Optical Coherence Tomography (OCT)-assessed Minimum Lumen Area (MLA) during the control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Coronary Computed Tomography Angiography (CCTA) assessed MLA at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Target Lesion Failure (TLF) at 1-year
Tidsramme: 1 Year
|
TLF is defined as Cardiac death, Target Vessel-MI (TV-MI), and Clinically-Driven Target Lesion Revascularization (CD-TLR)
|
1 Year
|
|
TLF at 2-years
Tidsramme: 2 Years
|
TLF is defined as Cardiac death, TV-MI, and CD-TLR
|
2 Years
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
CCTA-assessed plaque burden at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CCTA-assessed plaque burden post PCI
Tidsramme: 1 Week
|
1 Week
|
|
|
CCTA-assessed plaque burden at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
CCTA-assessed lipid pool volume at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CCTA-assessed lipid pool volume post PCI
Tidsramme: 1 Week
|
1 Week
|
|
|
CCTA-assessed lipid pool volume at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Computed Tomography Fractionated Flow Reserve (CT-FFR) at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CT-FFR at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Shear stress at lesion level at baseline measured by Elucid software
Tidsramme: Baseline
|
Baseline
|
|
|
Shear stress at lesion level at 1-year measured by Elucid software
Tidsramme: 1 Year
|
1 Year
|
|
|
OCT-assessed thrombus volume at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
OCT-assessed thrombus volume at control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
|
|
OCT-assessed area of stenosis post index procedure
Tidsramme: Periprocedural
|
Periprocedural
|
|
|
OCT-assessed area of stenosis post control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
|
|
OCT-assessed lumen gain
Tidsramme: Periprocedural and Day 2-3
|
Difference between control and index MLA
|
Periprocedural and Day 2-3
|
|
OCT-assessed lipid arc at control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Patologiske prosesser
- Hjertesykdommer
- Infarkt
- Nekrose
- Myokardiskemi
- Iskemi
- Patologiske tilstander, tegn og symptomer
- Hjerteinfarkt
- Kirurgiske prosedyrer, operativ
- Endovaskulære prosedyrer
- Vaskulære kirurgiske inngrep
- Kardiovaskulære kirurgiske inngrep
- Minimalt invasive kirurgiske inngrep
- Karbohydrater
- Glykosaminoglykaner
- Polysakkarider
- Heparin
- Perkutan koronar intervensjon
Andre studie-ID-numre
- 3W-RCG-2
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .